Calmark signs new distributor agreement for Sweden with Mediq

Calmark Sweden AB (publ) announced today that an exclusive distributor agreement has been signed with the company Mediq Sverige AB regarding Calmark's test for newborns.

Mediq Sverige AB was founded in 1985 and is part of the international healthcare group Mediq Group, which is Northern Europe's largest distributor of medical technology solutions. The group has its headquarters in the Netherlands and subsidiaries in 13 European countries.

‘At Mediq Sverige AB, we work with quality products from established suppliers. We therefore see the possibility of a collaboration with Calmark Sweden AB as an obvious choice which is completely in line with our motto - for the good of the patient!’ says Afsaneh Safari Nasab - Sales Manager Laboratory division Mediq Sweden. ‘We are very excited to establish this collaboration with Calmark and its unique product for point of care (POC), which will make a big difference for newborn babies and for the healthcare staff working in the children's clinics, but also for the entire care chain. I look forward to a nice and long-term collaboration between Mediq and Calmark.’

‘I am both proud and happy about this distribution agreement as Mediq has the organization in place that is needed to succeed in launching our products to the Swedish hospitals’, says Magdalena Tharaldsen, Director International Business Development for Calmark. ‘Mediq has already demonstrated a fantastic drive and a strong desire to work with us and our Neo products. I expect a quick sales start!’

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
 

For more information about Calmark Sweden AB, please contact:

Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50
E-post: camilla.arneving@calmark.se
www.calmark.se 

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.